Encompass Health (NYSE:EHC) Earns "Buy (B+)" Rating from Weiss Ratings

Key Points

• Encompass Health's stock was reaffirmed with a "Buy (B+)" rating by Weiss Ratings, with a consensus price target of $139.86.
• Multiple analysts, including those from Truist Financial and UBS Group, have raised their price targets on Encompass Health, now ranging from $140.00 to $160.00.
• Encompass Health reported earnings of $1.40 per share for the last quarter, exceeding the consensus estimate, and expects FY 2025 EPS guidance of $5.120 - $5.340.

Encompass Health (NYSE:EHC - Get Free Report)'s stock had its "buy (b+)" rating reiterated by investment analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

EHC has been the topic of several other reports. Truist Financial lifted their price objective on Encompass Health from $135.00 to $140.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. UBS Group lifted their price objective on Encompass Health from $140.00 to $150.00 and gave the company a "buy" rating in a research note on Thursday, October 2nd. Bank of America lifted their price objective on Encompass Health from $145.00 to $160.00 and gave the company a "buy" rating in a research note on Wednesday, September 10th. Finally, KeyCorp lifted their price objective on Encompass Health from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to data from MarketBeat.com, Encompass Health has a consensus rating of "Buy" and a consensus price target of $139.86.

Encompass Health Trading Down 0.6%

NYSE EHC traded down $0.80 during trading hours on Wednesday, hitting $124.40. 535,866 shares of the company's stock were exchanged, compared to its average volume of 607,583. The business's 50 day moving average is $122.20 and its 200-day moving average is $116.09. Encompass Health has a 12-month low of $87.85 and a 12-month high of $127.86. The firm has a market capitalization of $12.53 billion, a P/E ratio of 24.34, a price-to-earnings-growth ratio of 2.19 and a beta of 0.93. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06.

Encompass Health (NYSE:EHC - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.20. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a return on equity of 17.83% and a net margin of 9.22%.The firm's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.11 earnings per share. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. As a group, analysts anticipate that Encompass Health will post 4.8 EPS for the current fiscal year.

Insider Transactions at Encompass Health

In other Encompass Health news, EVP Patrick William Tuer sold 1,020 shares of Encompass Health stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the sale, the executive vice president directly owned 18,846 shares in the company, valued at $2,329,177.14. The trade was a 5.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Encompass Health

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Guided Capital Wealth Management LLC increased its holdings in Encompass Health by 3.6% during the 3rd quarter. Guided Capital Wealth Management LLC now owns 19,305 shares of the company's stock worth $2,452,000 after purchasing an additional 679 shares during the last quarter. Nilsine Partners LLC increased its holdings in Encompass Health by 2.6% during the 3rd quarter. Nilsine Partners LLC now owns 28,380 shares of the company's stock worth $3,605,000 after purchasing an additional 724 shares during the last quarter. GAMMA Investing LLC increased its holdings in Encompass Health by 5.7% during the 3rd quarter. GAMMA Investing LLC now owns 3,967 shares of the company's stock worth $504,000 after purchasing an additional 214 shares during the last quarter. Corient Private Wealth LLC increased its holdings in Encompass Health by 22.3% during the 2nd quarter. Corient Private Wealth LLC now owns 20,409 shares of the company's stock worth $2,503,000 after purchasing an additional 3,721 shares during the last quarter. Finally, Osaic Holdings Inc. grew its position in shares of Encompass Health by 7.2% in the 2nd quarter. Osaic Holdings Inc. now owns 13,721 shares of the company's stock worth $1,682,000 after acquiring an additional 919 shares in the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.